Announcements Trials
Browse Landscape

Phase

Phase 2 56Phase 3 20Phase 1/2 15Phase 1 15Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Vomiting 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Plasmacytoma 1POEMS Syndrome 1Obesity 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Nausea 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Brain Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

fludarabine 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2inebilizumab 1Sirolimus 1Positron-Emission Tomography 1Pemetrexed 1Lenalidomide 1Interleukin-6 1Hyperbaric Oxygenation 1Hydroxychloroquine 1Filgrastim 1Dexamethasone 1Bortezomib 1Blood Specimen Collection 113-valent pneumococcal vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasms, Plasma Cell × Dexamethasone × Clear all
NCT01861340 2018-09-10

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
20 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡